menu
    • menu

    Company profile for Helixmith

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Our flagship product, Engensis (VM202), is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF) through simple intramuscular injections. Engensis is being studied in clinical trials to determine whether it can provide safe and efficacious treatment effects for diabetic peripheral neuropathy (DPN), diabetic foot ulcer (DFU), and coronary artery disease (CAD) among other indications. Th...
    Our flagship product, Engensis (VM202), is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor (HGF) through simple intramuscular injections. Engensis is being studied in clinical trials to determine whether it can provide safe and efficacious treatment effects for diabetic peripheral neuropathy (DPN), diabetic foot ulcer (DFU), and coronary artery disease (CAD) among other indications. The US FDA has granted orphan drug and fast track designations for Engensis for the potential treatment of Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Helixmithkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    21, Magokjungang 8-ro 7-gil, Gangseo-gu, Seoul 07794
    Telephone
    Telephone
    82.2.2102.7200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.helixmith.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/helixmith/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Helixmith releases topline data on phase 2a trial of Lou Gehrig’s disease drug
    Helixmith releases topline data on phase 2a trial of Lou Gehrig’s disease drug

    05 Sep 2022

    // KOREABIOMED

    http://www.koreabiomed.com/news/articleView.html?idxno=14534

    KOREABIOMED
    05 Sep 2022
    Share Share
    Helixmith Announces 50% Enrollment in its Clinical Trial for COVID-19
    Helixmith Announces 50% Enrollment in its Clinical Trial for COVID-19

    01 Dec 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/helixmith-announces-50-enrollment-in-its-clinical-trial-for-covid-19-involving-tadios-301434530.html

    PRNEWSWIRE
    01 Dec 2021
    Share Share
    Helixmith Announces First Patient Enrolled in Ph3 Study of Engensis (VM202)
    Helixmith Announces First Patient Enrolled in Ph3 Study of Engensis (VM202)

    18 Nov 2020

    // PRWEB

    https://www.prweb.com/releases/helixmith_announces_first_patient_enrolled_in_phase_3_study_of_engensis_vm202_for_diabetic_peripheral_neuropathy/prweb17550435.htm

    PRWEB
    18 Nov 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search